CGON241220C30000
- 2.25
- 0.000.00%
CG Oncology Newsroom
Reported Earlier, CG Oncology Prices $204.4M Public Offering Of 8M Common Shares At $28/Share
CG Oncology: Morgan Stanley, Goldman Sachs AMong Managers for Offering >CGON
CG Oncology Oncology Has Granted Underwriters Option for Additional 1,200,000 Shares >CGON
CG Oncology Offering Price Set at $28.00 Per Share >CGON
Why CG Oncology (CGON) Stock Is Down 9%
CG Oncology Announces Proposed Public Offering of 7.3M Shares
CG Oncology Announces Proposed Public Offering
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $66
Insider Sale: Director at $CGON (CGON) Sells 750 Shares
Express News | RBC Capital Reiterates Outperform on CG Oncology, Maintains $66 Price Target
A Quick Look at Today's Ratings for CG Oncology(CGON.US), With a Forecast Between $55 to $86
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Analysts Offer Insights on NA Companies: Rubrik, Inc. Class A (RBRK) and CG Oncology, Inc. (CGON)
Demystifying CG Oncology: Insights From 7 Analyst Reviews
Promising Clinical Results and Strategic Positioning: CG Oncology Recommended as a Buy
CG Oncology, Inc.: A Strong Buy on Promising NMIBC Treatment Cretostimogene
Analysts' Top NA Picks: GE Vernova Inc. (GEV), CG Oncology, Inc. (CGON)
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate
CG Oncology Reports Promising Phase 3 Trial Results
CG Oncology Announced Topline Data From The Phase 3 BOND-003 Trial In Patients With High-risk Non-muscle Invasive Bladder Cancer Unresponsive To Bacillus Calmette Guerin Demonstrating 74.5% Of Patients Achieved A Complete Response, After Receiving...